Sustaining Medical Research: Consensus Is Just The Beginning

Throughout my 35-year career, I have joyfully observed the dramatic growth of medical research and biotechnology. I've had the good fortune, over time, to witness this evolution as a participant in each of the medical-research enterprise's three sponsoring environments: government, academia, and industry. More than anything this diverse experience has instilled in me a powerful belief that any improvement in the health and well-bei

Written byLeon Rosenberg
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Throughout my 35-year career, I have joyfully observed the dramatic growth of medical research and biotechnology. I've had the good fortune, over time, to witness this evolution as a participant in each of the medical-research enterprise's three sponsoring environments: government, academia, and industry.

More than anything this diverse experience has instilled in me a powerful belief that any improvement in the health and well-being of people, any progress toward humankind's fundamental desire to live longer, healthier lives, depends on the contributions of medical research-- whether basic or applied, whether centered in the laboratory or clinic, whether nurtured by government, academia, or industry.

This experience also has shaped my perspective that science has only begun to realize its vast potential to prevent, diagnose, treat, and cure disease. Today, we are on the brink of uncovering the basic mechanisms responsible for such diseases as cancer, Alzheimer's, and diabetes. We're tracking down human ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies